newsfilter
← Latest News
GlobeNewswire·

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Appointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and potential 2027 launch of aglatimagene besadenovec in localized prostate cancer NEEDHAM, Mass., June 25,